BACKGROUND AND PURPOSE: Assessment of prognostic factors might influence treatment decisions in patients with brain metastases. Based on large studies, the diagnosis-specific graded prognostic assessment (GPA) score is a useful tool. However, patients with unknown or rare primary tumours are not represented in this model. A pragmatic approach might be use of the first GPA version which is not limited to specific primary tumours. PATIENTS AND METHODS: This retrospective analysis examines for the first time whether the GPA is a valid score in patients not eligible for the diagnosis-specific GPA. It includes 71 patients with unknown primary tumour, bladder cancer, ovarian cancer, thyroid cancer or other uncommon primaries. Survival was evaluated in uni- and multivariate tests. RESULTS: The GPA significantly predicted survival. Moreover, improved survival was seen in patients treated with surgical resection or radiosurgery (SRS) for brain metastases. The older recursive partitioning analysis (RPA) score was significant in univariate analysis. However, the multivariate model with RPA, GPA and surgery or SRS versus none showed that only GPA and type of treatment were independent predictors of survival. CONCLUSION: Ideally, cooperative research efforts would lead to development of diagnosis-specific scores also for patients with rare or unknown primary tumours. In the meantime, a pragmatic approach of using the general GPA score appears reasonable.
BACKGROUND AND PURPOSE: Assessment of prognostic factors might influence treatment decisions in patients with brain metastases. Based on large studies, the diagnosis-specific graded prognostic assessment (GPA) score is a useful tool. However, patients with unknown or rare primary tumours are not represented in this model. A pragmatic approach might be use of the first GPA version which is not limited to specific primary tumours. PATIENTS AND METHODS: This retrospective analysis examines for the first time whether the GPA is a valid score in patients not eligible for the diagnosis-specific GPA. It includes 71 patients with unknown primary tumour, bladder cancer, ovarian cancer, thyroid cancer or other uncommon primaries. Survival was evaluated in uni- and multivariate tests. RESULTS: The GPA significantly predicted survival. Moreover, improved survival was seen in patients treated with surgical resection or radiosurgery (SRS) for brain metastases. The older recursive partitioning analysis (RPA) score was significant in univariate analysis. However, the multivariate model with RPA, GPA and surgery or SRS versus none showed that only GPA and type of treatment were independent predictors of survival. CONCLUSION: Ideally, cooperative research efforts would lead to development of diagnosis-specific scores also for patients with rare or unknown primary tumours. In the meantime, a pragmatic approach of using the general GPA score appears reasonable.
Authors: John H Suh; Gregory M M Videtic; Amr M Aref; Isabelle Germano; Brian J Goldsmith; Joseph P Imperato; Karen J Marcus; Michael W McDermott; Mark W McDonald; Roy A Patchell; H Ian Robins; C Leland Rogers; Aaron H Wolfson; Franz J Wippold; Laurie E Gaspar Journal: Curr Probl Cancer Date: 2010 May-Jun Impact factor: 3.187
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: J Sehouli; K Pietzner; P Harter; K Münstedt; S Mahner; A Hasenburg; O Camara; P Wimberger; D Boehmer; K J Buehling; R Richter; K El Khalfaoui; G Oskay-Ozcelik Journal: Ann Oncol Date: 2010-05-03 Impact factor: 32.976
Authors: Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: D Rades; L Dziggel; B Segedin; I Oblak; V Nagy; A Marita; S E Schild; N T Trang; M T Khoa Journal: Strahlenther Onkol Date: 2013-06-07 Impact factor: 3.621
Authors: D Rades; L Dziggel; B Segedin; I Oblak; V Nagy; A Marita; S E Schild; N T Trang; M T Khoa Journal: Strahlenther Onkol Date: 2013-06-07 Impact factor: 3.621
Authors: Carsten Nieder; Jan Norum; Astrid Dalhaug; Gro Aandahl; Kirsten Engljähringer Journal: Support Care Cancer Date: 2013-05-18 Impact factor: 3.603